Language
English
Publication Date
3-17-2026
Journal
The Journal of Infectious Diseases
DOI
10.1093/infdis/jiaf571
PMID
41313671
PMCID
PMC13017142
PubMedCentral® Posted Date
11-28-2025
PubMedCentral® Full Text Version
Post-print
Abstract
This study of a measles-vectored vaccine for chikungunya virus (MV-CHIK) was a Phase 1 randomized, double-blinded, placebo-controlled trial with varying intervals between the 2 doses. The 6 cohorts each had 30 subjects, of which 25 received MV-CHIK and 5 received placebo. The 5 × 105 TCID50 dose was superior to the 5 × 104 TCID50 dose, and longer dosing intervals resulted in higher titers in the high dose groups. Mild to moderate injection site and systemic reactogenicity was common but brief. There was no evidence of prolonged vaccine-related arthralgia.
Keywords
Humans, Double-Blind Method, Adult, Male, Chikungunya Fever, Chikungunya virus, Female, Antibodies, Viral, Middle Aged, Young Adult, Viral Vaccines, Measles virus, Immunogenicity, Vaccine, Adolescent, Healthy Volunteers, chikungunya, vaccine, phase 1 trial, measles-vectored vaccine
Published Open-Access
yes
Recommended Citation
Winokur, Patricia; Hegmann, Theresa E; El Sahly, Hana M; et al., "A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults" (2026). Faculty, Staff and Students Publications. 8818.
https://digitalcommons.library.tmc.edu/baylor_docs/8818